JPRN-jRCT2071220006已完成1 期
Phase 1, Single and Multiple Topically Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of M119102 in Healthy Adult Subjects.
Tomoyuki Nishiura0 个研究点目标入组 16 人开始时间: 2022年4月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 44age old（—）
- 性别
- Male
入选标准
- •(1)Healthy men who are 20 to 44 years of age at the time of informed consent.
- •(2)BMI of 18.5 to 24.9 kg/m2
排除标准
- •(1)Individuals with a history or merger of hepatic, renal, cardiac and other cardiovascular, gastrointestinal, hematologic, blood, endocrine, respiratory, or other diseases considered inappropriate for paticipation in the clinical study.
- •(2)Individuals who are judged to be clinically abnormal by the principal (sub) investigator based on clinical tests, vital signs, and electrocardiogram.
- •(3)Individuals who are judged to be unsuitable as subject by the principal (sub) investigator.
研究者
相似试验
招募中
1 期
A trial to learn about a study drug (STAR-0215) in adults with hereditary angioedemaCTIS2022-502953-32-01Astria Therapeutics Inc.53
未知
1 期
A Single-center, Single- and Multiple-Dose Phase 1 Study to Evaluate the Safety and Pharmacokinetics of TAK-114 in Healthy Adult Japanese and Caucasian Male SubjectsJPRN-jRCT2080222640TAKEDA PHARMACEUTICAL COMPANY LTD.82
招募中
1 期
A Phase 1 Single and Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of SZN-043, a Novel Bispecific Fusion Protein Targeting ASGR1 and ZNRF3/RNF43, in Healthy Volunteers and Subjects with Liver CirrhosisAlcoholic HepatitisInflammatory and Immune System - Other inflammatory or immune system disordersLiver CirrhosisACTRN12622000392763Surrozen Operating, Inc.40
已完成
1 期
PAT-SM6 in Patients with Recurrent In-Transit Cutaneous MelanomaRecurrent in-transit cutaneous melanomaCancer - Malignant melanomaSkin - Other skin conditionsACTRN12610000733077Patrys Limited9
进行中（未招募）
不适用
A double-blind, randomised, multiple dose, Phase III, multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases. - Not ApplicableEUCTR2007-006195-11-SKAlgeta ASA900